Comparison of the efficacy of salmeterol/fluticasone propionate combination in Japanese and Caucasian asthmatics

Respiratory Medicine

Volumn 101, Issue 12, 2007, Pages 2488-2494

  Kawai, M ^a   Kempsford, R ^b   Pullerits, T ^c   Takaori, S ^d   Hashimoto, K ^e   Takemoto, Y ^f,g   Lotvall J ^c  

^a Kawai Chest Clinic   (Japan)

^b GLAXOSMITHKLINE   (United Kingdom)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d Kouseikai Takaori Hospital Medical Corporation   (Japan)

^e Development and Medical Affairs Division   (Japan)

^f TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^g SeedSeek   (Japan)

Author keywords

Asthma; Ethnicity; Japanese; Plethysmography

Indexed keywords

ADOAIR; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; SALBUTAMOL; SALMETEROL; UNCLASSIFIED DRUG;

ADULT; AIRWAY CONDUCTANCE; ARTICLE; ASTHMA; BRONCHODILATING ACTIVITY; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; JAPANESE; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AGED; AIRWAY RESISTANCE; ALBUTEROL; ANALYSIS OF VARIANCE; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; ASTHMA; BODY HEIGHT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; JAPAN; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; RESPIRATORY FUNCTION TESTS; SWEDEN; TREATMENT OUTCOME;

EID: 35448975251     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.07.001     Document Type: Article

References (23)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. National Institutes of Health, 2002. NIH publication no. 02-3659.
2. Shapiro G., Lumry W., Wolfe J., et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 161 (2000) 527-534
3. Greening A.P., Ind P.W., Northfield M., and Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344 (1994) 219-224
4. Woolcock A., Lundback B., Ringdal N., and Jacques L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153 (1996) 1481-1488
5. Condemi J.J., Goldstein S., Kalberg C., Yancey S., Emmett A., and Rickard K. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Ann Allergy Asthma Immunol 82 (1999) 383-389
6. Busse W., Koenig S.M., Oppenheimer J., et al. Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. J Allergy Clin Immunol 111 (2003) 57-65
7. Nelson H.S., Busse W.W., Kerwin E., et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 106 (2000) 1088-1095
8. Ringdal N., Eliraz A., Pruzinec R., et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 97 (2003) 234-241
9. Davies B., Brooks G., and Devoy M. The efficacy and safety of salmeterol compared to theophylline: a meta-analysis of nine controlled studies. Respir Med 92 (1998) 256-263
10. Adachi M., Morikawa A., and Ishihara K. Asthma insights & reality in Japan (AIRJ). Arerugi-Jan J Allergol 51 (2002) 411-420
11. Rabe K.F., Adachi M., Lai C.K., et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 114 (2004) 40-47
12. Asthma prevention and management guideline 2003, Japan (updated from JGL 1998). Japan, 2003, JGL 2003.
13. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.C. European Community for coal and steel. Lung volumes and forced ventilatory flows. Report working party standardisation of lung function tests. Official statement of the European Respiratory Society. Eur Respir J Suppl. 16 (1993) 5-140
14. Aubier M., Pieters W.R., Schlosser N.J., and Steinmetz K.O. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 93 (1999) 876-884
15. Kavuru M., Melmed J., Gross G., et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 105 (2000) 1108-1116
16. 1: a meta-analysis. Am J Respir Crit Care Med 167 7 (2003) A142
17. Van Noord J.A., Smeets J., Clement J., Van de Woestijne K.P., and Demedts M. Assessment of reversibility of airflow obstruction. Am J Respir Crit Care Med 150 (1994) 551-554
18. Nielsen K.G., and Bisgaard H. Discriminative capacity of bronchodilator response measured with three different lung function techniques in asthmatic and healthy children aged 2 to 5 years. Am J Respir Crit Care Med 164 (2001) 554-559
19. Derks M.G., Ventresca P., Arvidsson P., Wright A.M., Palqvist M., and Lotvall J. Twenty-four hour duration of effect of salmeterol 200 microgram on airway conductance in healthy volunteers. Am J Respir Crit Care Med 167 7 (2003) A364
20. Tan E.F., Atkinson G., Sasso R., Mitchell W., and Ward J.K. Use of specific airways conductance (sGaw) in healthy volunteers (HVs) to determine bronchodilator dose-duration of action (DoA) relationship and therapeutic index (TI) of inhaled salmeterol. Am J Respir Crit Care Med Abstracts Issue (2006) A78
21. Jacobs D.R., Nelson E.T., Dontas A.S., Keller J., Slattery M.L., and Higgins M. Are race and sex differences in lung function explained by frame size? The CARDIA Study. Am Rev Respir Dis 146 (1992) 644-649
22. Whittaker A.L., Sutton A.J., and Beardsmore C.S. Are ethnic differences in lung function explained by chest size?. Arch Dis Child Fetal Neonatal Ed 90 (2005) F423-F428
23. Light R.W. Clinical pulmonary function testing, exercise testing and disability evaluation. Chest medicine: essentials of pulmonary and critical care medicine. 2nd ed (1990), Williams and Wilkins, Philadelphia